SGLT2 Inhibitor Medications and Starting Doses
For a patient with type 2 diabetes and an A1c of 6.9%, the available SGLT2 inhibitors with proven cardiovascular and renal benefits are: canagliflozin 100 mg daily, dapagliflozin 10 mg daily, and empagliflozin 10 mg daily. 1, 2, 3
Available SGLT2 Inhibitors
The SGLT2 inhibitor class includes five medications, though three have the strongest evidence base from cardiovascular outcomes trials:
Primary Options with Cardiovascular Outcomes Data:
Canagliflozin: Start at 100 mg orally daily 2, 3
- Can increase to 300 mg daily if eGFR ≥60 mL/min/1.73 m² and additional glycemic control needed
- FDA-approved to reduce risk of MI, stroke, CV death, and reduce risk of end-stage kidney disease in diabetic nephropathy with albuminuria 2
Additional SGLT2 Inhibitors:
- Ertugliflozin: Available but with less cardiovascular outcomes data 4, 5
- Sotagliflozin: SGLT1/2 dual inhibitor, primarily studied in heart failure 6, 5
Clinical Context for Your Patient (A1c 6.9%)
This patient's A1c is already near or at goal, so the decision to use an SGLT2 inhibitor should be driven by cardio-renal protection rather than glycemic control alone. 1, 7, 8 The 2022 KDIGO guidelines explicitly state that SGLT2 inhibitors should be used "regardless of glycemia" in appropriate patients 1.
When to Prioritize SGLT2 Inhibitors at This A1c:
The strongest indications for SGLT2 inhibitor therapy independent of A1c include:
- Chronic kidney disease: eGFR 20-60 mL/min/1.73 m² and/or albuminuria (especially ≥200 mg/g) 1, 6
- Heart failure: Particularly with reduced ejection fraction 2, 7, 6
- Established atherosclerotic CVD: Prior MI, stroke, revascularization 7, 8
- High cardiovascular risk: Age ≥55 with coronary/carotid/peripheral artery stenosis >50%, LVH, eGFR <60, or albuminuria 7, 8
Practical Initiation Approach
Before starting an SGLT2 inhibitor at this A1c level 1:
Assess hypoglycemia risk: If the patient is on insulin or sulfonylurea, consider dose reduction before initiating SGLT2 inhibitor to prevent hypoglycemia, especially since A1c is already at 6.9%
Assess volume status: If on diuretics or history of volume depletion/AKI, consider diuretic dose reduction
Check eligibility: Confirm eGFR ≥20 mL/min/1.73 m² 1
Screen for contraindications:
- Active genital infections
- History of diabetic ketoacidosis
- Active foot ulcers (relative contraindication requiring careful shared decision-making) 7
- Immunosuppression 1
eGFR-Based Dosing Modifications
- Canagliflozin: Maximum 100 mg daily if eGFR 30-59; do not use if eGFR <30 2, 3
- Dapagliflozin: Not recommended for glycemic control if eGFR <45; contraindicated if eGFR <30 2
- Empagliflozin: Do not initiate if eGFR <45; discontinue if persistently <45 2, 3
Critical caveat: These eGFR restrictions apply to glycemic efficacy, not cardiovascular/renal benefits. The 2022 KDIGO guidelines recommend use down to eGFR 20 mL/min/1.73 m² for cardio-renal protection 1. The glycemic benefit diminishes with declining kidney function, but cardiovascular and renal protective effects persist 3, 6.
Patient Education Priorities
Sick day protocol: Temporarily withhold during illness, excessive exercise, or alcohol intake; maintain hydration; monitor glucose and ketones more frequently 1
Perioperative management: Withhold day of day-stay procedures; withhold ≥2 days before procedures requiring hospitalization or bowel preparation 1
Genital hygiene: Counsel on increased risk of genital mycotic infections (more common in women) 1
Expected Acute Changes
Anticipate a small acute drop in eGFR (typically 3-5 mL/min/1.73 m²) within the first 2-4 weeks, which is hemodynamic and generally not a reason to discontinue therapy 1. This represents reduced intraglomerular pressure and is associated with long-term renal protection.